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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose: Increased mortality has been reported in patients treated with vanco-
mycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with high minimum
inhibitory concentration (MIC) values within the susceptibility range. However, this finding
has not been verified in hemodialysis patients, who have much higher invasive MRSA infection
rates than nondialysis patients. We aimed at comparing vancomycin MICs between hemodial-
ysis and nondialysis patients, and identifying predictors of high vancomycin MICs and infection-
related mortality in hemodialysis patients with MRSA bacteremia.
Methods: Patients with MRSA bacteremia from January 2008 through December 2009 were
enrolled. Vancomycin MIC was determined for each first isolate using the Etest method. Clin-
ical characteristics and vancomycin MICs were compared between hemodialysis and nondialy-
sis patients. Factors associated with high vancomycin MIC (2 mg/mL) and infection-related
mortality in hemodialysis patients were analyzed.
Results: A total of 162 MRSA bacteremia episodes were identified. Forty-four (27.0%) isolates
were obtained from hemodialysis patients and 118 (73.0%) from nondialysis patients. Diabetes
(63.3% vs. 39.8%, p Z 0.007) and prior vancomycin exposure in 30 days (31.8% vs. 12.7%,
p Z 0.005) were more prevalent in hemodialysis group than in nondialysis group. A higherInfectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General
nter, No. 325 Cheng-Kung Road, Section 2, Nei-hu, Taipei 114, Taiwan.
edu.tw (K.-M. Yeh).
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16 L.-P. Kan et al.prevalence of vancomycin MIC of 2 mg/mL was observed in hemodialysis group in comparison
with nondialysis group (11.4% vs. 1.7%, pZ 0.016). In following analyses of hemodialysis group,
patients with initial presentation of septic shock had a higher risk of vancomycin MIC of 2 mg/
mL than nonseptic shock patients (100.0% vs. 38.5% p Z 0.014). Infection-related mortality
was associated with age, Acute Physiology and Chronic Health Evaluation II (APACHE-II) score
>15, presence of septic shock, receipt of mechanical ventilation, and failure to remove source
of bacteremia in univariate analysis.
Conclusion: Hemodialysis patients with MRSA bacteremia are more likely to have a high vanco-
mycin MIC (2 mg/mL) compared with nondialysis patients. Infection-related mortality is associ-
ated with the patient’s clinical manifestations, including age, APACHE-II score >15, presence
of septic shock, receipt of mechanical ventilation, and failure to remove source of bacteremia.
Treatment selection should be tailored according to the patient’s clinical condition.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Staphylococcus aureus is the most common pathogen of
bloodstream infections (BSIs) in hemodialysis patients.1,2
In 2005, invasive methicillin-resistant S. aureus (MRSA)
infections occurred in 45.2/1000 dialysis patients, a rate
more than 100 times higher than in nondialysis patients.3
Patients with MRSA bacteremia who are undergoing hemo-
dialysis have a five-fold higher risk for death and >100%
higher hospital costs than uninfected patients undergoing
hemodialysis.4
Vancomycin is one of the most commonly administered
antimicrobial agents in hemodialysis patients, because of
both high risk of systemic MRSA infections and ease of
administration.5 Despite its sustained in vitro microbiolog-
ical inhibitory activities, emerging data suggest that van-
comycin may be less effective against MRSA infections with
minimum inhibitory concentrations (MICs) at the higher end
of the susceptibility range.6 Patients undergoing hemodi-
alysis with MRSA bacteremia had been studied in the United
States,7 but no local data are available in Taiwan. We
conducted this study to identify and compare the clinical
characteristics and vancomycin MICs between hemodialysis
and nondialysis patients with MRSA bacteremia. Factors
associated with high vancomycin MIC and infection-related
mortality in hemodialysis group were analyzed.Materials and methods
Study design and patients
This retrospective study was conducted at Tri-Service
General Hospital, a 1700-bed primary care and tertiary
referral center in northern Taiwan. A list of patients with
MRSA bacteremia from January 2008 through December 2009
was retrieved from the hospital’s clinical microbiology
laboratory database. The patients were divided into two
groups. Hemodialysis group comprised all patients who had
undergone hemodialysis for more than 3 months prior to
enrollment; the remaining patients were classified as non-
dialysis group. Demographic data, comorbidities, Charlson
Comorbidity Index, Acute Physiology and Chronic HealthEvaluation II (APACHE-II) score, initial presentation of septic
shock, surgery within 30 days, vancomycin exposure within
30 days, receipt of mechanical ventilation, use of vascular
access device, vancomycin MICs, and infection-related
mortality were retrospectively collected for all patients.
Additionally, causes of hemodialysis, source of bacteremia,
removal of source of bacteremia, administration of empirical
antimicrobial agents, presence of persistent bacteremia,
and mortality rate within 14 and 28 days after onset of
bacteremia were analyzed in hemodialysis group.
Definition
MRSA bacteremia was defined as the presence of at least one
set of blood culture yielding MRSA. Comorbidities were
defined as diseases that cause functional impairment and/or
predispose patients to infection, such as alcoholism
(consumption of >100 g of alcohol per day), chronic
obstructive pulmonary disease, dementia, diabetes, heart
failure, hematological neoplasms, immunosuppressive
therapy (>10 mg of prednisolone daily within 4 weeks, or
other agents used as antineoplastic chemotherapy or to
prevent organ rejection), liver cirrhosis, solid neoplasms,
and valvular heart disease. Causes of hemodialysis were
identified by either renal biopsy pathology report or medical
record. Septic shock was diagnosed on the basis of standard
clinical definition.8 Hospital-onset BSI was defined as
bacteremia occurring >48 hours after hospital admission.
Surgery within 30 days was defined as operation under either
general or local anesthesia in the past 30 days. All catheters
used at onset of bacteremia were recorded. Tunneled cath-
eters were passed under the skin from the insertion site to
a separate exit site, where the catheter and its attachments
emerge from underneath the skin (Por-A-Cath or double
lumen catheter, for instance). Any dose of vancomycin
exposurewithin 30 dayswas analyzed. Persistent bacteremia
was defined as growth of MRSAwith identical antibiogram on
Day 7 or after, within 30 days of the first positive blood
culture. Infection-related mortality was defined as death
occurred (1) within 7 days after positive blood cultures or (2)
prior to resolution of signs and symptoms ofMRSAbacteremia
or (3) 7 days after the onset of MRSA bacteremia without any
obvious cause other than bacteremia.
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Only one MRSA isolate per patient was included in the
microbiological portion of this study. All isolates were
identified using routine bacteriological procedures. Methi-
cillin susceptibility testing was performed using the disk
diffusion method, in accordance with the criteria of the
Clinical and Laboratory Standards Institute (CLSI).9 Vanco-
mycin MIC was determined using the Etest method,
according to the manufacturer’s guidelines. A suspension of
saline calibrated to the 0.5-McFarland turbidity standard
was plated onto MuellereHinton agar, onto which Etest
strips (AB BIODISK, Solna, Sweden) were applied. The plates
were incubated at 35C for 24 hours. The MIC was inter-
preted as the zone of inhibition that corresponded to
a concentration gradient on the Etest strips, according to
the manufacturer’s guidelines. Quality control was per-
formed using the CLSI-recommended reference strain
(ATCC 29213).9Table 1 Demographics and clinical characteristics of 162 patie
Variables Hemodialysis, n
Male sex 28 (63.6)
Age (y, mean  SD) 69.6  15.6
Comorbidity
Alcoholism 1 (2.3)
Chronic obstructive pulmonary disease 7 (15.9)
Dementia 5 (11.4)
Diabetes 28 (63.3)
Heart failure 16 (36.4)
Hematologic neoplasm 1 (2.3)
Immunosuppressive therapy 8 (18.2)
Liver cirrhosis 2 (4.5)
Solid neoplasm 8 (18.2)
Valvular heart disease 10 (22.7)
Charlson Comorbidity Index >5 20 (45.5)
APACHE-II score >15 24 (54.5)
Septic shock 20 (45.5)
Hospital onset 23 (52.3)
Surgery within 30 d 28 (63.6)a
Prior vancomycin exposure within 30 d 14 (31.8)
Receipt of mechanical ventilation 20 (45.5)
Vascular access device
Tunneled catheter 14 (31.8)c
Nontunneled catheter 9 (20.5)e
Fistula or graft 21 (47.7)
Vancomycin MIC
MIC 1.5 mg/mL 22 (50.0)
MIC Z 2 mg/mL 5 (11.4)
Infection-related mortality 18 (40.9)
APACHE-II Z Acute Physiology and Chronic Health Evaluation II; MIC
a Six patients underwent debridements, 12 arteriovenous shunt surg
b Twenty-four patients underwent debridements, 16 orthopedic sur
c Fourteen Hickman catheters.
d Two Port-A-Cath.
e Nine double-lumen catheters.
f Fifty-eight central venous catheters and six pulmonary artery cath
g Fistula or graft was not compared between hemodialysis and nondi
or graft.Statistical analysis
Categorical variables were compared using c2 test or
Fisher’s exact test, and the Student t test was used for
continuous variables. Multivariate logistic regression
models were used to assess the predictors of vancomycin
MIC of 2 mg/mL and the association with infection-related
mortality. All analyses were performed using SPSS version
15.0 (SPSS Inc., Chicago, IL, USA).Results
One hundred and sixty-two patients with MRSA bacteremia
were included during January 2008 through December 2009,
including 44 (27.0%) patients in hemodialysis and 118
(73.0%) patients in nondialysis group (Table 1). Patients
with acute renal failure on temporary hemodialysis, or with
end stage renal disease undergoing peritoneal dialysis werents with methicillin-resistant S. aureus bacteremia
Z 44 (%) Nondialysis, n Z 118 (%) p
81(68.6) 0.546
69.1  18.6 0.874
8 (6.8) 0.446
17 (14.4) 0.811
24 (20.3) 0.185
47 (39.8) 0.007
27 (22.9) 0.084
11 (9.3) 0.183
27 (22.9) 0.518
10 (8.5) 0.515
28 (23.7) 0.450
13 (11.0) 0.058
46 (39.0) 0.456
64 (54.2) 0.972
53 (44.9) 0.951
78 (66.1) 0.106
60 (50.8)b 0.146
15 (12.7) 0.005
61 (51.7) 0.480
2 (1.7)d <0.001
64 (54.2)f <0.001
0 dg
57 (48.3) 0.848
2 (1.7) 0.016
49 (41.5) 0.944
Z minimum inhibitory concentration; SD Z standard deviation.
eries, and 10 Hickman catheterizations.
geries, 10 abdominal surgeries, and 10 tracheostomies.
eters.
alysis patients because none of the nondialysis patients had fistula
18 L.-P. Kan et al.not identified in our study. The median age was 69.3 years
(range 20e97 years), and 67.2% patients were male. Clin-
ical characteristics of the patients are shown in Table 1.
Diabetes (63.3% vs. 39.8%, pZ 0.007) and prior vancomycin
exposure in 30 days (31.8% vs. 12.7%, pZ 0.005) were more
prevalent in hemodialysis group than in nondialysis group.
Tunneled catheter use was more prevalent in hemodialysis
group (31.8% vs. 1.7%, p < 0.001). All MRSA strains were
susceptible to vancomycin (MICs 0.5 to 2 mg/mL). The
prevalence of vancomycin MICs 1.5 mg/mL was similar in
hemodialysis and nondialysis groups in this study (50.0% vs.
48.3%, p Z 0.848). A higher prevalence of vancomycin MIC
of 2 mg/mL was observed in hemodialysis group than in
nondialysis group (11.4% vs. 1.7%, p Z 0.016).
Infection-related and Day 28 mortality of hemodialysis
and nondialysis patients with different vancomycin MICs are
illustrated in Fig. 1. Infection-related mortality ranged
between 42.1% and 60.0%, and Day 28 mortality between
40.0% and 50.0% in the two groups. No significant difference
in infection-related and Day 28 mortality could be noted
between hemodialysis and nondialysis groups regarding
different vancomycin MICs.
Factors associated with high vancomycin MIC (2 mg/mL)
in hemodialysis patients are analyzed in Table 2. In
univariate analysis, septic shock was associated with a high
vancomycin MIC of 2 mg/mL in hemodialysis group
(p Z 0.014, Table 2). No independent risk factor could be
identified in the stepwise logistic regression, with heart
failure, APACHE-II score >15, septic shock, and receipt of
mechanical ventilation as variables. Other causes ofFigure 1. (A) Infection-related and (B) Day 28 mortality
of hemodialysis and nondialysis patients with different vanco-
mycin MICs. No significant difference could be noted
between two groups regarding different minimum inhibitory
concentrations.hemodialysis in patients with vancomycin MIC <2 mg/mL
included two drug-related nephropathy and four unknown
causes. Other causes of MRSA bacteremia included one
MRSA pneumonia in patients with a vancomycin MIC of
2 mg/mL, one MRSA pneumonia, and two primary bacter-
emia in patients with vancomycin MIC <2 mg/mL (Table 2).
All hemodialysis patients with S. aureus bacteremia were
empirically treated with vancomycin, while pending the
antimicrobial susceptibility data. Time of initiation,
dosage, and trough level of vancomycin are presented in
Tables 2 and 3.
Infection-related mortality in hemodialysis group in this
study was 40.9% (Table 1). Univariate and multivariate
analyses using infection-related mortality as a dependent
variable were performed to identify factors associated with
infection-related mortality in hemodialysis group (Table 3).
In univariate analysis, age, APACHE-II score >15, presence
of septic shock, receipt of mechanical ventilation, and
failure to remove source of bacteremia were associated
with infection-related mortality. In the stepwise logistic
regression, no independent risk factor for infection-related
mortality was identified.Discussion
A higher prevalence of prior vancomycin exposure within 30
days in hemodialysis group than in nondialysis group was
observed in this study. Widespread use of glycopeptides,
especially vancomycin,3 is known to be associated with the
development of resistant organisms (vancomycin-resistant
Enterococcus and S. aureus).10 Evaluation of the patient’s
clinical condition and prudent use of vancomycin are
important due to the ever-changing bacterial resistance
patterns.
A higher prevalence of vancomycin MIC of 2 mg/mL was
observed in hemodialysis group in comparison with non-
dialysis group. Septic shock was associated with high van-
comycin MIC (2 mg/mL) in hemodialysis group, although not
an independent risk factor in this study. Several studies had
been conducted to determine factors predicting high van-
comycin MICs in patients with MRSA bacteremia. Patients
with a history of prior vancomycin exposure within 30 days
or infections in the intensive care unit (ICU) should be
considered for high risk of strains with high vancomycin
MICs (1.5 mg/mL).11 A clinical rule had been developed to
predict a vancomycin MIC of 2 mg/mL, which included age
>50 years, prior vancomycin exposure, history of MRSA
bacteremia, chronic liver disease, and presence of a non-
tunneled central venous catheter.12 One caseecontrol
study performed in hemodialysis patients with MRSA
bacteremia revealed that surgery within previous 6 months
and ICU admission were significant risk factors for high
vancomycin MIC (2 mg/mL). However, the role of prior
vancomycin exposure was not evaluated in the study.7
We found that age, APACHE-II score >15, presence of
septic shock, receipt of mechanical ventilation, and failure
to remove source of bacteremia were associated with
infection-related mortality in hemodialysis patients with
MRSA bacteremia. Prognostic factors associated
with mortality in general patients with MRSA bacteremia
include complications, acute severe clinical condition at
Table 2 Factors associated with high vancomycin MIC (2 mg/mL) in 44 hemodialysis patients with methicillin-resistant
S. aureus bacteremia
Variables High MIC Z 2 mg/mL
n Z 5 (%)
Low MIC <2 mg/mL
n Z 39 (%)
p
Male sex 5 (100.0) 23 (59.0) 0.141
Age (y, mean  SD) 75.2  9.4 68.9  16.2 0.403
Comorbidity
Alcoholism 0 (0.0) 1 (2.6) 1.000
Chronic obstructive pulmonary disease 0 (0.0) 7 (17.9) 0.574
Dementia 0 (0.0) 5 (12.8) 1.000
Diabetes 3 (60.0) 25 (64.1) 1.000
Heart failure 4 (80.0) 12 (30.8) 0.051
Hematologic neoplasm 1 (20.0) 0 (0.0) 0.114
Immunosuppressive therapy 2 (40.0) 6 (15.4) 0.219
Liver cirrhosis 1 (20.0) 1 (2.6) 0.217
Solid neoplasm 1 (20.0) 7 (17.9) 1.000
Valvular heart disease 1 (20.0) 9 (23.1) 1.000
Cause of hemodialysis
Chronic glomerulonephritis 0 (0.0) 2 (5.1) 1.000
Cystic kidney disease 0 (0.0) 1 (2.6) 1.000
Diabetic nephropathy 2 (40.0) 17 (43.6) 1.000
Hypertensive nephropathy 3 (60.0) 12 (30.8) 0.319
Others 0 (0.0) 6 (15.4) 1.000
Source of bacteremia
Skin and soft tissue 0 (0.0) 5 (12.8) 1.000
Bone and joint 1 (20.0) 1 (2.6) 0.217
Catheter related 2 (40.0) 21 (53.8) 0.658
Endocarditis or endovascular 1 (20.0) 11 (28.2) 1.000
Others 1 (20.0) 3 (7.7) 0.394
Charlson Comorbidity Index >5 4 (80.0) 16 (41.0) 0.160
APACHE-II score >15 5 (100.0) 19 (48.7) 0.053
Septic shock 5 (100.0) 15 (38.5) 0.014
Hospital onset 4 (80.0) 19 (48.7) 0.348
Surgery within 30 d 3 (60.0) 25 (64.1) 1.000
Prior vancomycin exposure within 30 d 2 (40.0) 12 (30.8) 0.647
Receipt of mechanical ventilation 4 (80.0) 16 (41.0) 0.160
Vascular access device
Tunneled catheter 3 (60.0) 11 (28.2) 0.307
Nontunneled catheter 0 (0.0) 9 (23.1) 0.566
Fistula or graft 2 (40.0) 19 (48.7) 1.000
Failure to remove source of bacteremia 2 (40.0) 16 (41.0) 1.000
Time of bacteremia source removal (d, mean  SD) 14.0  10.8 4.0  4.3 0.248
(n Z 3) (n Z 23)
Vancomycin treatment
Initiation within 24 h from bacteremia 4 (80.0) 22 (56.4) 0.634
1 g once per wk 3 (60.0) 15 (39.5) 0.634
1 g twice per wk 2 (40.0) 23 (60.5) 0.634
Vancomycin trough level (mean, mg/mL) 23.0  12.0 15.2  7.4 0.248
(n Z 2) (n Z 9)
Persistent bacteremia 2 (40.0) 15 (40.5) 1.000
Infection-related mortality 3 (60.0) 15 (38.5) 0.386
Mortality within 14 d 1 (20.0) 12 (30.8) 1.000
Mortality within 28 d 2 (40.0) 14 (35.9) 1.000
Multivariate analysis was performed with heart failure, APACHE-II score >15, septic shock, and receipt of mechanical ventilation as
variables, but failed to draw significance (p > 0.05). APACHE-II Z Acute Physiology and Chronic Health Evaluation II; MIC Z minimum
inhibitory concentration; SD Z standard deviation.
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Table 3 Factors associated with infection-related mortality in 44 hemodialysis patients with methicillin-resistant S. aureus
bacteremia
Variables Infection-related
mortality, n Z 18 (%)
Survival,
n Z 26 (%)
p
Male sex 12 (66.7) 16(61.5) 0.728
Age (y, mean  SD) 76.1  8.3 65.2  17.9 0.010
Vancomycin MIC
MIC  1.5 mg/mL 10 (55.6) 12 (46.2) 0.540
MIC Z 2 mg/mL 3 (16.7) 2 (7.7) 0.370
Comorbidity
Alcoholism 1 (5.6) 0 (0.0) 0.409
Chronic obstructive pulmonary disease 3 (16.7) 4 (15.4) 1.000
Dementia 3 (16.7) 2 (7.7) 0.386
Diabetes 13 (72.2) 15 (57.7) 0.325
Heart failure 8 (44.4) 8 (30.8) 0.354
Hematologic neoplasm 0 (0.0) 1 (3.8) 1.000
Immunosuppressive therapy 4 (22.2) 4 (15.4) 0.697
Liver cirrhosis 1 (5.6) 1 (3.8) 1.000
Solid neoplasm 2 (11.1) 6 (23.1) 0.439
Valvular heart disease 5 (27.8) 5 (19.2) 0.716
Cause of hemodialysis
Chronic glomerulonephritis 0 (0.0) 2 (7.7) 0.505
Cystic kidney disease 0 (0.0) 1 (3.8) 1.000
Diabetic nephropathy 10 (55.6) 9 (34.6) 0.168
Hypertensive nephropathy 6 (33.3) 9 (34.6) 0.930
Others 2 (11.1) 4 (15.4) 1.000
Source of bacteremia
Skin and soft tissue 4 (22.2) 1 (3.8) 0.142
Bone and joint 1 (5.6) 1 (3.8) 1.000
Catheter related 5 (27.8) 18 (69.2) 0.007
Endocarditis or endovascular 5 (27.8) 7 (26.9) 1.000
Others 3 (16.7) 1 (3.8) 0.289
Charlson Comorbidity Index >5 9 (50.0) 11 (42.3) 0.614
APACHE-II score >15 18 (100.0) 6 (23.1) <0.001
Septic shock 14 (77.8) 6 (23.1) <0.001
Hospital onset 11 (61.1) 12 (46.2) 0.329
Surgery within 30 d 9 (50.0) 19 (73.1) 0.118
Prior vancomycin exposure within 30 d 6 (33.3) 8 (30.8) 0.858
Receipt of mechanical ventilation 13 (72.2) 7 (26.9) 0.003
Vascular access device
Tunneled catheter 7 (38.9) 7 (26.9) 0.402
Nontunneled catheter 4 (22.2) 5 (19.2) 1.000
Fistula or graft 7 (38.9) 14 (53.8) 0.329
Failure to remove source of bacteremia 12 (66.7) 6 (23.1) 0.004
Time of bacteremia source removal (d, mean  SD) 8.7  8.9 4.1  4.6 0.268
(n Z 6) (n Z 20)
Vancomycin treatment
Initiation within 24 h from bacteremia 9 (50.0) 17 (65.4) 0.307
1 g once per wk 8 (47.1) 10 (38.5) 0.576
1 g twice per wk 9 (52.9) 16 (61.5) 0.576
Vancomycin trough level (mean, mg/mL) 15.5  10.1 17.6  7.2 0.703
(n Z 5) (n Z 6)
Persistent bacteremia 9 (52.9) 8 (32.0) 0.175
Multivariate analysis was performed with age, APACHE-II score >15, septic shock, receipt of mechanical ventilation, and failure to
remove source of bacteremia as variables, but failed to draw significance (p > 0.05). APACHE-IIZ Acute Physiology and Chronic Health
Evaluation II; MIC Z minimum inhibitory concentration; SD Z standard deviation.
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MRSA bacteremia in hemodialysis patients 21onset, and inappropriate empiric treatment.13 Several
studies have suggested that age and MRSA nasal carriage
are predictive of mortality in hemodialysis patients with
MRSA bacteremia.14,15 Li et al14 suggested that age older
than 65 years is independently associated with a higher risk
of death in hemodialysis patients with S. aureus bacter-
emia. MRSA nasal carriers were found to have a 4.99-fold
increased risk of infection-related mortality compared with
noncarriers in an outpatient hemodialysis population.15
Failure to treat MRSA bacteremia with vancomycin MICs
1 mg/mL was first addressed by Sakoulas et al.6 Subse-
quent studies showed a higher mortality rate in high van-
comycin MIC group (MIC 2 mg/mL),16e20 or treatment failure
with vancomycin MICs 121 or 1.5 mg/mL.11 Few studies
have focused on the impact of high vancomycin MIC on
hemodialysis patients with MRSA bacteremia. In our study,
high vancomycin MIC (2 mg/mL) was not associated with
infection-related mortality in hemodialysis group. In
a caseecontrol study performed among hemodialysis
patients with MRSA bacteremia, patients with high vanco-
mycin MIC (2 mg/mL) and low vancomycin MIC (0.5 mg/mL)
did not differ significantly with regard to mortality in
multivariate analysis.7
According to the Infectious Diseases Society of America
guideline for MRSA infections, for isolates with a vancomy-
cin MIC of 2 mg/mL, the patient’s clinical response should
determine whether the use of vancomycin should be
continued or not, independent of vancomycin MICs (A-III).22
In a literature review by van Hal et al,23 alternative anti-
MRSA agents should be considered for MRSA BSIs with van-
comycin MIC 2 mg/mL, as determined by Etest method,
especially in patients with persistent disease.23 There are
very little data supporting better survival rates with alter-
native antibiotics for MRSA BSIs. One retrospective casee
control trial showed better outcome with daptomycin than
with vancomycin for the treatment of MRSA BSIs with van-
comycin MICs of 1.5e2 mg/mL.24 A study involving 470 MRSA
isolates in Taiwan showed that isolates with vancomycin
MIC of 2 mg/mL were all susceptible to linezolid and tige-
cycline, whereas most isolates (98.8%) were susceptible to
daptomycin.25 Future clinical trials for alternative anti-
MRSA agents in high vancomycin MIC group are mandatory.
There are some limitations to this study. This study
enrolled only patients from a single site. Institutional
differences in patient populations, antibiotic prescribing
patterns, and resistance patternsmay affect its applicability
to other institutions. Vancomycin exposure within 30 days
may be biased due to retrospective nature of the study and
possible missing record in other ambulatory hemodialysis
clinics. The possibility of patient-to-patient transmission of
high vancomycin MIC strains cannot be excluded due to lack
of molecular studies to determine whether one or several
clones are driving the observed results. MRSA carriage
screening was not performed in our hemodialysis patients.
The effect of concomitantly administered antibiotics should
be a covariate in future analysis. The failure to identify
predictors for high vancomycin MIC (2 mg/mL) and lack of
association with infection-related mortality may be of less
statistical power due to limited study number. Enrollment of
more patients is mandatory in future clinical studies.
In conclusion, a higher prevalence of vancomycin MIC of
2 mg/mL was identified in hemodialysis group than innondialysis group. More prevalent vancomycin exposure
was observed in hemodialysis group. Although not being
a significant risk factor for high vancomycin MIC, vanco-
mycin should be used cautiously due to possible develop-
ment of resistant organisms and potentially predictive of
high vancomycin MICs as addressed by other studies.11,12
Infection-related mortality is associated with the
patient’s clinical manifestations, including age, APACHE-II
score >15, presence of septic shock, receipt of mechan-
ical ventilation, and failure to remove source of bacter-
emia. Treatment selection should be tailored according to
the patient’s clinical condition.Conflicts of interest
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